PEPTOKING
EN

WHO adds semaglutide, tirzepatide and other GLP-1 drugs to its essential medicines list

Regulatory

The World Health Organization's updated Model List of Essential Medicines (24th edition) added the GLP-1 receptor agonists semaglutide, dulaglutide and liraglutide and the dual GIP/GLP-1 receptor agonist tirzepatide. The listing is only for glucose-lowering treatment in adults with type 2 diabetes who have both obesity (body mass index of 30 or more) and either established cardiovascular disease or chronic kidney disease; it does not cover obesity or weight loss on their own. WHO said high prices of medicines such as semaglutide and tirzepatide are limiting access to them.

Sources

  1. 01WHO updates list of essential medicines to include key cancer, diabetes treatments(opens the source in a new tab) World Health Organization
  2. 02WHO Adds GLP-1s to List of Essential Medicines(opens the source in a new tab) BioSpace

Peptides involved

  1. ApprovedSemaglutideGLP-1 receptor agonist31
  2. ApprovedTirzepatideDual GIP and GLP-1 receptor agonist39
  3. ApprovedDulaglutideGLP-1 receptor agonist (Fc fusion protein)31
  4. ApprovedLiraglutideGLP-1 receptor agonist31